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ABSTRACT.
Purpose: To examine preoperative anti-inflammatory treatment on recovery
from cataract surgery in eyes of diabetic patients.
Methods: A Prospective randomized clinical trial. One hundred and three eyes
of 103 patients with diabetes undergoing routine cataract surgery were
randomized (1:1) not to receive any preoperative anti-inflammatory medication
or to receive preoperative topical anti-inflammatory medication with a combi-
nation of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml). All eyes
received postoperative anti-inflammatory combination therapy for 3 weeks.
Recovery from surgery was recorded by a structured home questionnaire.
Clinical outcome parameters were recorded at 28 days and 3 months.
Results: Patient age and gender distribution, and all baseline ophthalmic and
systemic parameters were comparable between the study groups. After surgery,
conjunctival injection lasted 2.4  1.7 days (mean  SD) and irritation of the
eye 3.3  3.9 days in eyes without preoperative treatment, when compared to
1.6  1.6 days (p = 0.067) and 2.4  4.0 days (p = 0.431), respectively, in eyes
with preoperative treatment. At 28 days, central subfield macular thickness
(CSMT) increased 2.2  20.2 lm in eyes without preoperative treatment, when
compared 0.1  25.2 lm (p = 0.670) in eyes with preoperative treatment. At
3 months, the respective CSMT change from baseline was 1.5  26.9 lm and
3.4  26.2 lm (p = 0.762). None of the eyes were reported with pseudophakic
cystoid macular oedema (PCME) in either group.
Conclusion: Lack of preoperative anti-inflammatory treatment does not impair
recovery from surgery or predispose diabetic patients to increased risk of PCME
in eyes postoperatively treated with combination therapy of prednisolone acetate
and nepafenac.
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Introduction
Cataract surgery with modern tech-
niques is considered a cost-effective and
safe healthcare intervention. Pseu-
dophakic cystoid macular oedema
(PCME) is among the most common
complications of cataract surgery, even
in the absence of intraoperative com-
plications or other risk factors (Kessel
et al. 2014; Chu et al. 2016; Grzy-
bowski et al. 2016). Postoperative ster-
ile inflammation predisposes eyes to
breakdown of the blood–retinal barrier
(BRB), increases vascular permeability
and the risk for PCME (Ersoy et al.
2013). Patients with diabetes are at
recognized risk for PCME (Chu et al.
2016). Particularly, coexistence of dia-
betic retinal manifestations, insulin
dependence and poor glycemic control
has been linked with the risk for
macular oedema after surgery (Ylinen
et al. 2017).
The effectiveness, productivity and
safety of health care can be improved
by systematically withdrawing out-
dated practices that are not based on
evidence, are not sufficiently effective
or may even be harmful. Such methods
may have unfavourable balance of
anticipated benefits and risks, they
may cause unnecessary costs, and are
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inferior to other available treatment
options. At the present, ophthalmic
check-ups after routine cataract sur-
gery may become unnecessary (Elo-
ranta & Falck 2017; Westborg &
Monestam 2017). Moreover, use of
topical antibiotics pre- and postopera-
tively is being abandoned since it gives
no additional benefit over perioperative
intracameral antibiotic administra-
tion (Lundstrom et al. 2007, ESCRS
Endophthalmitis Study Group, 2007,
Friling et al. 2013; Kessel et al. 2017).
The development of streamlined clini-
cal eye care processes has resulted in
substantial reduction in lead times
without compromising patient satisfac-
tion (Lindholm et al. 2018). Similarly,
standardization of high-volume eye
health services has led to discarding
preoperative ophthalmic check-ups for
the majority of outpatients requiring
cataract surgery. Nevertheless, achiev-
ing optimal outcomes and preventing
late complications in high-risk patients
requires diligent care which also neces-
sitates adequate medical treatment.
Diabetic patients for instance, with a
risk to develop PCME, are encouraged
to be systematically followed by oph-
thalmologists. In clinical practice for
high-risk patients regarding PCME,
pre- and postoperative medical inter-
ventions with a combination of topical
anti-inflammatory drugs are employed
to minimize postoperative inflamma-
tion (Donnenfeld et al. 2006; Yavas
et al. 2007; Kim et al. 2010; Wielders
et al. 2015).
The purpose of this study was to
assess whether preoperative anti-
inflammatory medication has any addi-
tional benefit in recovery from surgery,
intraocular inflammation and macular
oedema after surgery, when the anti-
inflammatory treatment after unevent-
ful cataract removal was a combination
of potent steroid and nonsteroidal anti-
inflammatory drug (NSAID). These
results may supplement to our knowl-
edge in planning the optimal schedule
and anti-inflammatory treatment pro-
tocol for patients with diabetes.
Materials and Methods
Study design
The study was a prospective random-
ized clinical trial. One hundred and
three eyes of 103 patients with diabetes
were admitted as per the national
guidelines for the management of
cataract in the Department of Oph-
thalmology, Kymenlaakso Central
Hospital, Kotka, Finland. Patients
were enrolled between March 2017
and March 2018.
Patients were randomized in two
groups: those not receiving any preop-
erative anti-inflammatory medication
(later in text referred as PRE) and
those receiving prednisolone acetate
(Pred Forte, 10 mg/ml, Allergan,
Inc. Irvine, CA) and nepafenac
(Nevanac, 1 mg/ml, Novartis, Basel,
Switzerland) combination therapy
three times a day (t.i.d) for 3 days
before surgery (later in text referred as
PRE+). All patients received a combi-
nation of prednisolone acetate and
nepafenac t.i.d for 3 weeks as postop-
erative anti-inflammatory medication.
Clinical outcome parameters were
recorded at 28 days and 3 months.
The study was conducted according
to the tenets of the Declaration of
Helsinki and was approved by the
Research Director and Chief Medical
Officer of the Kymenlaakso Central
Hospital, the FinnishMedicinesAgency
Fimea and the Institutional Review
Board of Helsinki University Hospital
(EU Clinical Trials Register Number:
2016-004514-10).
Randomization
The study was conducted as a ran-
domized, prospective single-centre
study (hrrg.fi/en/clinicaltrials/cataract/).
Patients were randomized by a research
technician into two groups for the
different anti-inflammatory medication
protocols described above.
Inclusion criteria
The study subjects were of 60–90 years
of age and were eligible for cataract
surgery under the Current Care Guide-
lines of Cataract Surgery of the Finnish
Medical Society, Duodecim (updated
in 2013).
Exclusion criteria
Exclusion criteria for the study included
prior or active wet age-related macular
degeneration, retinal vein/artery occlu-
sion, retinal detachment or optic neuri-
tis, previous intraocular procedures
(excluding fundus laser photocoagula-
tion), prior or scheduled anti-vascular
endothelial growth factor (anti-VEGF)
treatment andmyopia above6.0 diop-
tres. Alcohol abuse, thyroid diseasewith
abnormal thyroid-stimulating hormone
(TSH) levels, continuous use of anti-
inflammatory drugs and sensitivity to
any of the medications used during or
after the operation. Criteria for exclu-
sion were also intraoperative complica-
tions (such as iris prolapse, use of
sutures or posterior capsule tear) or
failure to use the anti-inflammatory
medication as prescribed.
Patients
Prior to the 28-day control visit four
patients were withdrawn at their own
request or failure to attend the prede-
termined control visit (one patient in
the PRE and three patients in the
PRE+ study group) (Table 1). Between
the 28-day and 3-month postoperative
visits, five patients were withdrawn at
their own request or failure to attend
the predetermined control visit (four
patients in the PRE and one patient
in the PRE+ study group) (Table 1).
After these dropouts, a total of 99
eyes were included in the analysis at the
28-day postoperative visit and 94 eyes
at the 3-month postoperative visit
(Table 1).
Surgery
Prior to the surgery, all eyes were
prepared with the combination of
tropicamide (Oftan Tropicamid,
5 mg/ml), phenylephrine hydrochloride
(Oftan Metaoksedrin, 100 mg/ml),
levofloxacin (Oftaquix, 5 mg/ml) and
oxybuprocaine hydrochloride (Oftan
Table 1. Flow chart.
Intention-to-treat
N = 103 eyes
Randomization PRE PRE+
At baseline N = 52 eyes N = 51 eyes
At 28 days N = 51 eyes N = 48 eyes
At 3 months N = 47 eyes N = 47 eyes
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Obucain, 4 mg/ml), all from Santen
Pharmaceutical Co. Ltd, Osaka, Japan.
A standardized phacoemulsification
technique was used in all cataract
surgeries (hrrg.fi/en/videos/cataract/).
A 2.75 mm clear cornea incision was
followed by capsulorrhexis, pha-
coemulsification (divide and conquer)
and intraocular lens placement into the
capsular bag. An Ozil phacoemulsifi-
cation handpiece and a 0.9 mm 30-
degree beveled Kelman tip were used in
the phacoemulsification system
(Infiniti, Alcon, Fort Worth, TX). In
all cases, anaesthesia was topical.
Hyaluronic acid 1.6%-chondroitin sul-
phate 4.0% (DisCoVisc, Alcon) was
used as ophthalmic viscosurgical
device. Preloaded aspheric hydropho-
bic single-piece monofocal intraocular
lenses (PCB00, Tecnis IOL in iTec
delivery system, Abbott Medical Optics
Inc./Johnson & Johnson Vision, Santa
Ana, CA; and AU00T0, AcrySof IQ,
SN60WF in UltraSertTM delivery sys-
tem, Alcon) were used.
In addition to the preoperative use
of mydriatics at preparation for the
surgery, intracameral phenylephrine
was applied in all operations after the
clear cornea incision. Antimicrobial
medication included intraoperative
intracameral cefuroxime (Aprokam,
Laboratoires Thea, Clermont-Ferrand,
France). No postoperative antimicro-
bial medication was used. Cataract
surgeries were performed by four spe-
cialists and two experienced residents
in ophthalmology.
Structured home questionnaire
On the day of surgery, all patients
received a structured take-home
questionnaire. These home question-
naires were crosschecked by the
patient and a research technician at
the 28-day postoperative visit, before
collecting the data. The regularity of
eye drop use, date of conjunctival
injection and eye irritation cessation,
time to reach maximal and stable
visual acuity and overall satisfaction
were recorded. Moreover, self-moni-
tored fasting and postprandial blood
glucose levels were recorded for
28 days after surgery.
Clinical evaluation
The operating physician examined the
patients preoperatively. DR was graded
on a four-stage severity classification as
none, background, moderate to severe
nonproliferative or proliferative DR.
Furthermore, all diabetic patients
belonged to regular screening system
for diabetic retinopathy according to
the Current Care Guideline for Dia-
betic retinopathy of the Finnish Med-
ical Society, Duodecim (updated in
2015).
Preoperative measurements before
initiation of anti-inflammatory medica-
tion were performed by a trained
research technician whom the patients
also visited at 28 days and 3 months.
An auto-refractometer (ARK-1s,
NIDEK Co. Ltd, Aichi, Japan) was
used to evaluate postoperative visual
acuity. Intraocular pressure was mea-
sured by rebound tonometry (iCare
tonometer, Revenio Group, Vantaa,
Finland).
Aqueous flare was recorded by a
laser flare metre (FM-600, Kowa
Company, Ltd., Nagoya, Japan).
The mean of five reliable aqueous
flare measurements was used in the
analysis. Macular thickness was
reported according to the ETDRS
retinal thickness map. Central subfield
macular thickness (CSMT; defined as
the mean thickness in the central
1000-lm diameter area), parafoveal
and perifoveal thickness (defined as
the mean thickness in a concentric
ring 1.0–3.0 mm and 3.0–6.0 mm
around the fovea) and total macular
volume (TMV; calculated for the
central 6.0 mm area) were recorded
by a spectral-domain optical coher-
ence tomography (SD-OCT; Heidel-
berg Eye Explorer Version 1.9.10.0
and HRA/SPECTRALIS Viewing
Module Version 6.0.9.0, Heidelberg
Engineering GmbH, Heidelberg, Ger-
many). Follow-up 30-frame SD-OCT
scans were performed with AUTORES-
CAN
TM software. CSMT, parafoveal
and perifoveal thickness, and TMV
values obtained at 28 days and
3 months were compared to those
prior to cataract surgery and
initiation of anti-inflammatory medi
cation.
Macular thickening was defined as
CSMT ≥ 10% from the baseline with
no signs of macular oedema at any
postoperative time-point. The diagno-
sis of PCME was confirmed together
with two physicians based on clinical
appearance and OCT findings. No
pre-existing macular oedema on the
preoperative OCT was accepted. The
criteria for PCME were CSMT ≥ 10%
from baseline with cystoid changes
near the fovea at any postoperative
time-point.
Sample size
The primary outcome measure was
changed in CSMT. The sample size
estimation was based on the study
hypothesis that the preoperative anti-
inflammatory treatment group is supe-
rior to the postoperative only treat-
ment group in preventing CSMT
change 28 days after cataract surgery.
CSMT was expected to change +16 lm
in the postoperative only treatment
group, with a standard deviation of
8 lm. The effect size was set at 5 lm;
thus, the CSMT was expected to
change +11 lm in the preoperative
treatment group, with a standard devi-
ation of 8 lm. With sampling ratio of
1:1, the sample size needed to be at
least 41 in each group to provide a test
power of 80%. The significance level
was set at 5%. With 20% estimated
dropout rate, the final estimate was 52
in each group.
Statistical analyses
Data are given as mean  standard
deviation, except for the absolute num-
bers and proportions for the nominal
scale. IBM SPSS Statistics 24 (IBM
Corp., Armonk, NY) was used for
statistical analysis. For two-group
comparisons at a given time-point,
data were analysed with the two-factor
chi-squared test for categorical
variables, with Student’s t-test for
continuous variables and with Mann–
Whitney U-test for nonparametric
variables. p ≤ 0.05 was considered sta-
tistically significant.
Results
Baseline variables
Baseline variables regarding (i) the
patient (age, gender, HbA1c level and
insulin dependence), (ii) ophthalmic
characteristics (the degree of DR,
aqueous flare, CDVA, CSMT and
IOP) and (iii) systemic medication were
comparable between the two study
groups. Baseline characteristics are
summarized in Table 2.
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Subjective irritation symptoms and patient
satisfaction
Response rate to the structured home
questionnaire for patients controlled at
28 days was 65% (33 of 51 patients) in
the PRE group and 67% (32 of 48
patients) in the PRE+ group.
Duration of conjunctival injection
after surgery was statistically non-
significant between the PRE (2.4 
1.7 days) and PRE+ (1.6  1.6 days)
groups (p = 0.067, Table 3). Irritation
of the eye after surgery lasted compa-
rably between the groups: 3.3 
3.9 days and 2.4  4.0 days, respec-
tively (p = 0.431, Table 3).
Moreover, the time to reach max-
imal and stable visual acuity (VA)
(4.5  3.4 days versus 5.0  4.8 days;
p = 0.455, Table 3) and overall
patient satisfaction at 28 days on a
scale of 0–10 (9.2  0.8 versus
9.5  0.8; p = 0.166, Table 3) did
not differ between the PRE and
PRE+ groups.
Aqueous flare, macular thickness and
presence of pseudophakic cystoid macular
oedema
Aqueous flare change at 28 days was
+4.7  12.3 pu/msec in the eyes in the
PRE-, compared with 1.9  13.0 pu/
msec in the PRE+ group (p = 0.016,
Table 4). At 3 months, change in the
aqueous flare was +2.6  12.4 pu/msec
in the PRE and 0.2  14.8 pu/msec
in the PRE+ group (p = 0.356,
Table 4).
CSMT change at 28 days was
+2.2  20.2 lm in the PRE- and
+0.1  25.2 lm in the PRE+ group
(p = 0.670, Table 4). At 3 months,
CSMT change was 1.5  26.9 lm
and 3.4  26.2 lm, respectively
(p = 0.762, Table 4).
Changes from the baseline for par-
afoveal and perifoveal thickness, and
total macular volume at 28 days and at
3 months did not differ between the
PRE and PRE+ groups (Table S1).
Furthermore, differences in CDVA
gain and IOP reduction at 28 days
and at 3 months were insignificant
between the study groups (p = NS,
Table 4).
At 28 days, macular thickening
(CSMT ≥ 10% for baseline with no
signs of cystoid changes) was observed
in four eyes in the PRE and two eyes
in the PRE+ groups. Importantly, at
3 months macular thickening was not
observed in any of the six eyes. During
the 3-month follow-up, no cases of
PCME were diagnosed in either study
group (Table 4).
Self-monitored blood glucose levels
during the 28-day follow-up after
cataract surgery were comparable
between the study groups (6.8 
1.6 mmol/l in the PRE- and 7.1 
1.9 mmol/l in the PRE+ group;
p = 0.670, Table S2). Postoperative
self-monitored blood glucose levels
did not correlate with aqueous flare
or CSMT change (p = NS, data not
shown).
Effect of the degree of diabetic retinopathy
on cataract surgery outcome measures
Finally, we analysed the outcome mea-
sures in eyes with (N = 6) and without
Table 2. Baseline variables.
PRE PRE+ p
Age (years) 74.9  8.3 76.6  6.4 0.246
Gender M:F (n/%) 27:25 (52:48) 26:25 (51:49) 0.924
HbA1c (mmol/mol)(%) 53.6  14.8 (7.1  1.4) 52.9  16.2 (7.0  1.5) 0.870
Insulin dependence (n/%) 21 (40) 23 (45) 0.629
Retinopathy (No:BG:NPDR:PDR) (n/%) 37:9:3:3 (71:17:6:6) 39:8:1:3 (76:16:2:6) 0.529
Aqueous flare (pu/ms) 13.5  10.5 16.1  13.7 0.292
CDVA (decimals) 0.35  0.20 (0.05–1.0) 0.37  0.19 (0.05–1.0) 0.561
CSMT (lm) 278.3  32.6 (227–360) 284.7  29.5 (232–363) 0.328
IOP (mmHg) 14.6  3.8 (8–24) 13.2  3.7 (7–22) 0.086
Systemic medication
ACE/AT2 (n/%) 25 (48) 32 (63) 0.134
b-blocker (n/%) 25 (48) 28 (55) 0.488
CCB (n/%) 14 (27) 16 (31) 0.619
Statin (n/%) 32 (62) 29 (57) 0.629
ACE = angiotensin-converting-enzyme inhibitor, AT2 = angiotensin II receptor antagonist, b-blocker = beta-blocker, BG = background retinopa-
thy, CCB = calcium channel blocker, CDVA = corrected distance visual acuity, CSMT = central subfield macular thickness, DM = diabetes
mellitus, HbA1c = glycated haemoglobin, IOP = intraocular pressure, NPRD = moderate and severe nonproliferative diabetic retinopathy,
PDR = proliferative diabetic retinopathy, pu = photon units, statin = HMG-CoA reductase inhibitor.
Baseline variables regarding patient and ophthalmic parameters. Data are given as mean (SD) and range (CDVA, CSMT and IOP) or absolute
numbers and proportion. For two-group comparisons, two-factor chi-squared test was used for qualitative data, Student’s t-test for continuous
variables and Mann–Whitney U-test for ordinal measurement scale in the level of retinopathy and CDVA.
Table 3. Home questionnaire outcomes.
PRE PRE+ p
Duration of conjunctival injection (days) 2.4  1.7 1.6  1.6 0.067
Duration of irritation of the eye (days) 3.3  3.9 2.4  4.0 0.431
Time to reach maximal and stable VA (days) 4.5  3.4 5.0  4.8 0.455
Satisfaction at 28 days (grade 1–10) 9.2  0.8 9.5  0.8 0.166
VA = visual acuity.
Data are given as mean (SD). For two-group comparisons, Student’s t-test was used for
continuous variables and Mann–Whitney U-test for ordinal measurement scale in patient
satisfaction grade.
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(N = 97) the proliferative form of DR
(PDR). Baseline HbA1c levels were
68.5  16.9 mmol/mol (8.4  1.5%)
in patients with PDR and
52.2  14.8 mmol/mol (6.9  1.4%)
in patients without PDR (p = 0.014,
data not shown).
At 28 days, CDVA gain and CSMT
change was 0.24  0.13 decimals and
+4.2  7.5 lm in patients with PDR,
compared to 0.47  0.31 decimals
(p = 0.210, Table 5) and +1.1 
23.1 lm (p = 0.745, Table 5) in
patients without PDR. At 3 months,
CDVA gain and CSMT change was
0.33  0.28 decimals and 0.8 
16.7 lm in patients with PDR com-
pared to 0.52  0.29 decimals (p =
0.285, Table 5) and 2.5  27.2 lm
(p = 0.831, Table 5) in patients with-
out PDR.
CDVA gain and CSMT change at
28 days and 3 months was comparable
between the PRE and PRE+ groups
in a subgroup of patients with PDR
(p = NS, data not shown) and in
another subgroup of patients without
PDR (p = NS, data not shown).
Discussion
The results of this study show that the
postoperative anti-inflammatory treat-
ment protocol with a combination of
potent steroid and NSAID was less
effective in controlling ocular inflam-
mation at 28 days, but equally effective
in recovery after surgery as the anti-
inflammatory protocol containing pre-
operative treatment for 3 days prior
the cataract surgery. Macular oedema
was observed in neither of the study
groups at 28 days and at 3 months.
The incidence of PCME according
to large registry-based studies was
higher among diabetic patients com-
pared to those without diabetes. Espe-
cially, the prevalence of PCME well
correlated with the stage of DR (Chu
et al. 2016). Unfortunately, these anal-
yses have been conducted in patients
with steroid monotherapy, excluding
patients receiving any prophylactic
NSAID therapy for PCME. Further-
more, concerns of overestimating dia-
betes as a risk factor for PCME have
been raised due to, for example, the
biased postoperative screening between
nondiabetic and diabetic patients and
the lack of pre-existing information on
their macular status (Kim & Grzy-
bowski 2017). Extensive multicentre
RCT in nondiabetic patients revealed
that combination treatment with brom-
fenac and dexamethasone reduced the
risk for clinically significant macular
oedema when compared to patients
treated with either drug alone (Wield-
ers et al. 2018a). Treating high-risk
patients for PCME with topical
NSAIDs may decrease the incidence
of macular oedema (Henderson et al.
2007). Randomized clinical trials have
previously demonstrated that anti-
inflammatory treatment with a combi-
nation of NSAID and steroid is more
effective than steroid monotherapy in
prevention of macular oedema in
patients with diabetic retinopathy
(Singh et al. 2012; Pollack et al. 2017).
Preoperative use of NSAIDs may
have potential to limit pain and miosis
during cataract surgery (Hoffman et al.
2016). Donnenfeld et al. have reported
that preoperative ketorolac treatment
started one to three days before catar-
act surgery and combined with post-
operative combination treatment with
prednisolone acetate significantly
reduced anterior chamber inflamma-
tory scores and improved visual acuity
in the immediate postoperative period
when compared to the group of
patients on preoperative ketorolac
treatment started one hour before
cataract surgery with postoperative
combination treatment and compared
with postoperative steroid only treat-
ment group (Donnenfeld et al. 2006).
In their study, no significant effect on
Table 4. Clinical parameter outcomes.
PRE PRE+ p
Aqueous flare (pu/msec)
Change at 28 days +4.7  12.3 1.9  13.0 0.016
Change at 3 months +2.6  12.4 0.2  14.8 0.356
CDVA (decimals)
Change at 28 days +0.44  0.31 +0.46  0.31 0.843
Change at 3 months +0.46  0.29 +0.53  0.30 0.410
CSMT (lm)
Change at 28 days +2.2  20.2 +0.1  25.2 0.670
Change at 3 months 1.5  26.9 3.4  26.2 0.762
IOP (mmHg)
Change at 28 days 3.1  3.9 1.7  2.5 0.050
Change at 3 months 3.5  4.0 3.1  3.1 0.676
PCME (N)
At 28 days – –
At 3 months – –
CDVA = corrected distance visual acuity, CSMT = central subfield macular thickness, IOP = in-
traocular pressure, PCME = pseudophakic cystoid macular oedema, pu = photon units.
Data are given as mean (SD). For two-group comparisons at a given time-point, continuous
variables were analysed with the Student’s t-test and ordinal measurement scale (CDVA) with the
Mann–Whitney U-test. p-value ≤ 0.05 in bold were considered significant.
Table 5. Recovery from cataract surgery in eyes with or without PDR.
PDR
N = 97
PDR+
N = 6 p
CDVA (decimals)
Change at 28 days +0.47  0.31 +0.24  0.13 0.210
Change at 3 months +0.52  0.29 +0.33  0.28 0.285
CSMT (lm)
Change at 28 days +1.1  23.1 +4.2  7.5 0.745
Change at 3 months 2.5  27.2 0.8  16.7 0.831
CDVA = corrected distance visual acuity, CSMT = central subfield macular thickness,
PDR = proliferative diabetic retinopathy.
Data are given as mean (SD). For two-group comparisons at a given time-point, continuous
variables (CSMT) were analysed with the Student’s t-test and ordinal measurement scale (CDVA)
with the Mann–Whitney U-test.
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the incidence of cystoid macular
oedema was observed (Donnenfeld
et al. 2006). In another study, Yavas
et al. found that preoperative treat-
ment with indomethacin for 3 days
before surgery combined with postop-
erative combination treatment with
prednisolone acetate resulted in signif-
icantly lower incidence of angiographic
cystoid macular oedema, when com-
pared to the postoperative combina-
tion treatment or steroid monotherapy
groups (Yavas et al. 2007). In both
studies, the postoperative only combi-
nation treatment represented relatively
high CME incidences. In the study of
Yavas et al., the incidence of CME at
three months was 15% as evidenced by
angiography (Yavas et al. 2007),
whereas in the study of Donnenfeld
et al., the incidence of CME at 2 weeks
was 12% as evidenced by OCT per-
formed to patients with a BCVA worse
than 20/30 (Donnenfeld et al. 2006).
Furthermore, in both studies diabetes
mellitus was an exclusion criterion. In
the study of Yavas et al., exclusion
criteria were also hypertension, cardiac
disease and topical or systemic drug
use (Yavas et al. 2007). Comparison of
treatment outcomes to those in our
study is also hindered by the lack of
pre- and postoperative data on macular
thickness and aqueous flare in previous
studies.
Regardless of progress in topical
anti-inflammatory therapy, optimal
prevention of PCME accounting cost-
effectiveness of the treatment protocol
needs further investigation (Kessel
et al. 2017). We have recently found
that systemic medications may have a
bearing on the incidence of PCME
(Danni et al. 2018a). When diabetes
was appropriately managed, eyes with-
out posterior segment manifestations
were not at increased risk for PCME
(Danni et al. 2018b), and no excess risk
of death, myocardial infarction or
stroke was observed, as compared with
the general population (Rawshani
et al. 2018). Information on cardiovas-
cular medicines and glycemic control
are particularly important when defin-
ing a prophylactic treatment protocol
for PCME of the patients with dia-
betes. As a NSAID regimen, we chose
to use nepafenac, which is one of the
most commonly used NSAIDs, and has
proven to be effective and well toler-
ated (Margulis et al. 2017; Ylinen et al.
2018). We analysed not only the
preoperative glycemic control, but also
the postoperative glucose levels, as
cataract surgery may positively affect
glycemic control (Bar-Oz et al. 2018).
Not only the posterior segment status
of diabetic patients, but also the
glycemic control pre- and postopera-
tively and systemic medication were
comparable between the study groups.
Of note, even the presence of the
proliferative form of diabetic retinopa-
thy was not associated with the devel-
opment of macular oedema with the
anti-inflammatory combination treat-
ment in our study.
For the PCME analysis, the patient
number in this study is relatively
small, and the follow-up of 3 months
is short. The incidence of clinically
significant CME after uneventful cat-
aract surgery is low even in the
diabetic population (from 3% to
4%) (Schmier et al. 2007; Chu et al.
2016; Wielders et al. 2018b). Late
occurrence of clinically significant
CME may develop, beyond the 3-
month follow-up period particularly
among patients with diabetic posterior
segment manifestations (Baker et al.
2013; Denniston et al. 2017). Thus,
larger patient series are necessary to
reach more reliable results, and in this
study, the effectiveness of anti-inflam-
matory combination treatment to
counteract PCME may have been
overestimated. Furthermore, it should
be noted that no patients had prior or
active DME in this study as prior or
scheduled anti-VEGF treatment was
one of the exclusion criteria.
Adding a NSAID to prednisolone
acetate treatment was associated with
reduced risk of macular oedema (Shor-
stein et al. 2015). Generally, however,
in diabetic patients fixed or tapering-
down schedule with topical NSAID is
longer than the 3 weeks adopted in this
study. As previously described, aque-
ous flare peaks within the first few days
after cataract surgery, after which the
levels decline rapidly in the first week
and return to baseline by 3 months
(Stock et al. 2011). High aqueous flare
levels by contrast were associated with
multiple pro-inflammatory and vasoac-
tive cytokines, and PCME develop-
ment (Ersoy et al. 2013; Noma et al.
2017). Aqueous flare remained slightly
elevated in the postoperative only
treatment group at 3 months and it
may be important for clinical practice
regarding late occurrence of macular
oedema. The longer anti-inflammatory
treatment may be especially important
in eyes with prior history of or manifest
DME.
In conclusion, our results emphasize
that diabetic patients without DME do
not require preoperative treatment pro-
tocol against PCME when the postop-
erative anti-inflammatory treatment is
adequate.
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